Stock Track | Relay Therapeutics Plummets 5.42% as Leerink Partners Slashes Target Price

Stock Track

May 06, 2025

Shares of Relay Therapeutics (RLAY) plummeted 5.42% in pre-market trading on Tuesday, following a significant target price cut by Leerink Partners. The healthcare company's stock faced pressure after the investment firm lowered its price target from $14 to $12, signaling reduced confidence in the company's near-term prospects.

The downward revision in the target price comes amidst mixed analyst opinions on Relay Therapeutics. While some analysts maintain a positive outlook on the company, others express caution, contributing to the stock's volatility. This divergence in expert views has likely added to investor uncertainty, further exacerbating the stock's decline.

Relay Therapeutics, known for its innovative approach in the healthcare sector, now faces increased scrutiny from investors. The company's ability to navigate these challenges and deliver on its pipeline will be crucial in regaining market confidence. As the trading day progresses, investors will be closely monitoring any additional analyst comments or company updates that could influence the stock's trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1150091327"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150091327\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150091327?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-06 21:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150091327","market":"sg","top_or_hot":-1,"title":"Stock Track | Relay Therapeutics Plummets 5.42% as Leerink Partners Slashes Target Price","media":"Stock Track","content":"<p>Shares of Relay Therapeutics (RLAY) plummeted 5.42% in pre-market trading on Tuesday, following a significant target price cut by Leerink Partners. The healthcare company's stock faced pressure after the investment firm lowered its price target from $14 to $12, signaling reduced confidence in the company's near-term prospects.</p>\n\n<p>The downward revision in the target price comes amidst mixed analyst opinions on Relay Therapeutics. While some analysts maintain a positive outlook on the company, others express caution, contributing to the stock's volatility. This divergence in expert views has likely added to investor uncertainty, further exacerbating the stock's decline.</p>\n\n<p>Relay Therapeutics, known for its innovative approach in the healthcare sector, now faces increased scrutiny from investors. The company's ability to navigate these challenges and deliver on its pipeline will be crucial in regaining market confidence. As the trading day progresses, investors will be closely monitoring any additional analyst comments or company updates that could influence the stock's trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Relay Therapeutics Plummets 5.42% as Leerink Partners Slashes Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Relay Therapeutics Plummets 5.42% as Leerink Partners Slashes Target Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-06 21:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Relay Therapeutics (RLAY) plummeted 5.42% in pre-market trading on Tuesday, following a significant target price cut by Leerink Partners. The healthcare company's stock faced pressure after the investment firm lowered its price target from $14 to $12, signaling reduced confidence in the company's near-term prospects.</p>\n\n<p>The downward revision in the target price comes amidst mixed analyst opinions on Relay Therapeutics. While some analysts maintain a positive outlook on the company, others express caution, contributing to the stock's volatility. This divergence in expert views has likely added to investor uncertainty, further exacerbating the stock's decline.</p>\n\n<p>Relay Therapeutics, known for its innovative approach in the healthcare sector, now faces increased scrutiny from investors. The company's ability to navigate these challenges and deliver on its pipeline will be crucial in regaining market confidence. As the trading day progresses, investors will be closely monitoring any additional analyst comments or company updates that could influence the stock's trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLAY","symbol_name":"Relay Therapeutics","start_time":0,"source_url":"","article_id":"1150091327","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150091327","pubTimestamp":1746539639,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Relay Therapeutics  plummeted 5.42% in pre-market trading on Tuesday, following a significant target price cut by Leerink Partners. The healthcare company's stock faced pressure after the investment firm lowered its price target from $14 to $12, signaling reduced confidence in the company's near-term prospects.The downward revision in the target price comes amidst mixed analyst opinions on Relay Therapeutics. While some analysts maintain a positive outlook on the company, others expres","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLAY":"Relay Therapeutics"},"translate_title":"Leerink Partners下调目标价，Relay Therapeutics股价暴跌5.42%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLAY":1},"content_text":"Shares of Relay Therapeutics (RLAY) plummeted 5.42% in pre-market trading on Tuesday, following a significant target price cut by Leerink Partners. The healthcare company's stock faced pressure after the investment firm lowered its price target from $14 to $12, signaling reduced confidence in the company's near-term prospects.\nThe downward revision in the target price comes amidst mixed analyst opinions on Relay Therapeutics. While some analysts maintain a positive outlook on the company, others express caution, contributing to the stock's volatility. This divergence in expert views has likely added to investor uncertainty, further exacerbating the stock's decline.\nRelay Therapeutics, known for its innovative approach in the healthcare sector, now faces increased scrutiny from investors. The company's ability to navigate these challenges and deliver on its pipeline will be crucial in regaining market confidence. As the trading day progresses, investors will be closely monitoring any additional analyst comments or company updates that could influence the stock's trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}